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Case report
Lamivudine treatment for chronic replicative hepatitis B virus
infection after allogeneic bone marrow transplantation
M Picardi, C Selleri, G De Rosa, A Raiola, L Pezzullo and B Rotoli
Division of Hematology, Federico II University, Naples, Italy
Summary:
The risk of severe hepatic damage in patients with
chronic hepatitis B virus (HBV) infection is well known;
more effective treatments for this infection are needed.
Lamivudine is being studied in immunocompetent and
immunosuppressed HBV infected patients. We report a
patient suffering from chronic replicative HBV infection
after allogeneic BMT, who responded to lamivudine
therapy. A 24-year-old woman with CML received an
allogeneic BMT from her HLA-identical sister in June
1992. Before transplant, her HBV status demonstrated
viral contact without active infection (HBsAb+,
HBcAb+ IgG, HBeAb+). Four months after BMT mild
chronic liver GVHD appeared, requiring immunosup-
pressive treatment. Antibodies to HBV completely dis-
appeared post-transplant. Acute icteric hepatitis
occurred 2 years later, with HBsAg+, high level of HBV-
DNA, HBeAg+ and HBcAb IgM+. Lamivudine 100
mg/day rapidly reduced transaminase levels and
effected HBV-DNA disappearance within 2 months. The
treatment was well tolerated; no hematological side-
effects occurred. This preliminary observation warrants
further investigation of lamivudine treatment in
bone marrow transplanted patients with active HBV
infection.
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Hepatitis B virus (HBV) infection is a serious epidemiolog-
ical and clinical problem in patients undergoing BMT. The
infection can progress to chronic liver disease, cirrhosis and
hepatocarcinoma; moreover, the reactivation of latent HBV
infection, which may lead to fulminant hepatitis, has been
reported at immune reconstitution after BMT.1 In European
BMT candidates the median prevalence of HBV infection
is 3.5% (range 0–15%).2,3 The use of positive hepatitis B
surface antigen (HBsAg+) donors increases the risk of sev-
ere liver disease in BMT recipients.1 Only a few drugs may
be effective for treating active HBV infection, including
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a-IFN, famciclovir and lamivudine. We report the use of
lamivudine for the treatment of chronic replicative HBV
infection in a patient who had undergone allogeneic BMT
for CML.
Case report
Ph-positive CML in chronic phase was diagnosed in a 24-
year-old woman in October 1990. At that time she had anti-
bodies against hepatitis B surface antigen (HBsAb), core
antigen (HBcAb, IgG), and e antigen (HBeAb). Pretrans-
plant treatment included hydroxyurea and a-IFN. In June
1992 she underwent allogeneic BMT from her HBsAg
negative HLA-identical sister, after conditioning with bus-
ulfan and cyclophosphamide. GVHD prophylaxis was CsA
and short-course MTX. Engraftment was documented on
day 25, when the neutrophil count reached 500/ml. Four
months later the patient showed increased transaminases,
bilirubin, alkaline phosphatase and g-glutamil-transferase;
her serum CsA level was in the therapeutic range
(900 ng/ml by Abbott Laboratories polyclonal assay
(Abbott Laboratories, Chicago, IL, USA)). A liver biopsy
documented hepatic GVHD; immunohistochemistry
showed absence of HBsAg and HBcAg in hepatocytes.
Immunosuppression was potentiated by the addition of
methylprednisolone (60 mg/day), and serum hepatic
enzymes and bilirubin decreased. After 6 months, CsA was
withdrawn and the patient was maintained with methylpred-
nisolone and azathioprine, owing to a moderate chronic
hepatic GVHD. Nine months after BMT, HBsAb and
HBeAb disappeared from the serum; after a further 8
months, HBcAb was also undetectable. Three years after
BMT the patient had an episode of acute icteric hepatitis
due to HBV infection: HBsAg, HBcAb IgM and HBeAg
became detectable in the serum. The disease remained
active for more than 1 year, with altered serum transamin-
ase (5 · NV); a high level of serum HBV-DNA (2400
pg/ml, Abbott Genostics TM liquid hybridization assay)
was found in December 1996. Hepato-splenic ultrasound
showed hepatomegaly with no signs of cirrhosis. The
patient refused a repeat liver biopsy. In February 1997,
treatment with lamivudine 100 mg/day orally was started.
Serum transaminases remained unchanged (5 · NV) for a
month, then showed a sudden increase to 20 · NV which
spontaneously subsided in 4 weeks, reaching values close
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to normal 4 months after the start of treatment. No lamivud-
ine side-effects were noticed during treatment. HBV-DNA
completely disappeared from the serum 2 months after the
start of treatment, concomitantly with the flare-up of trans-
aminases, and remained undetectable at the subsequent con-
trols. Five years after BMT, she is in continuous complete
hematological and cytogenetic remission from CML;
HBsAg is still present in the serum, while HBeAg has dis-
appeared. A mild increment of transaminase, g-glutamil
transferase and alkaline phosphatase persists, probably due
to the pre-existing chronic hepatic GVHD. The plan is to
interrupt lamivudine and continue azathioprine treatment.
Discussion
The standard treatment of chronic replicative HBV infec-
tion (defined as HBeAg, HbcAb IgM and HBV-DNA
positive) is high-dose a-IFN (a 16 week course with 10
MU, three times a week s.c.).4 However, this treatment is
effective in less than half of patients, and patients with very
high serum levels of HBV-DNA rarely respond.5 Side-
effects at this dosage include myalgia, fever, leuko- and
thrombocytopenia, neuropsychiatric disturbances and
induction of auto-antibodies. Moreover, in allogeneic bone
marrow transplanted patients high-dose a-IFN may facili-
tate GVHD development or may worsen pre-existing
GVHD, due to enhancement of immunologic reactivity.6
Lamivudine is a new nucleoside analogue which can be
administered orally, with strong activity against replicative
HBV infection. It is an inhibitor of reverse transcriptase
which is necessary to transcribe the HBV-RNA pregenome
into HBV-DNA.7,8 A preliminary study has shown that
lamivudine treatment may induce complete and sustained
suppression of HBV-DNA in patients with chronic rep-
licative HBV infection.8 In that study, most of the patients
treated had not responded to a-IFN therapy and it was
thought that the previous IFN treatment may have contrib-
uted to the subsequent success of lamivudine therapy. We
decided not to use a-IFN in our patient, in view of the
high serum HBV-DNA level and the risk of worsening the
coexisting hepatic GVHD. Even in the absence of a-IFN
treatment, after 4 months with lamivudine a marked
reduction of transaminases and complete suppression of
serum HBV-DNA were observed, in the absence of side-
effects; later, even HBeAg disappeared. Increased transam-
inase levels after the start of lamivudine treatment have
already been observed;7,8 our patient showed an amplifi-
cation of this phenomenon, with an acute hepatitis-like peak
followed by a spontaneous regression. It is worth noting
that at the dose used lamivudine did not show any hematol-
ogical toxicity. It is interesting that our patient cleared her
serum HBsAb, HBcAb and HBeAb after 9–17 months from
allogeneic BMT, and remained negative during the early
phase of hepatic GVHD (Figure 1). At that time, HBV
infection was considered highly unlikely on the basis of
liver histology, absence of viral particles on immunostain-
ing and negativity of serological markers. The subsequent
HBV infection behaved as a de novo infection (HBcAb
IgM+). Although we cannot categorically exclude a reinfec-
tion, the patient had not received any blood products during
Figure 1 Hepatitis B virus marker and transaminase modifications in the
reported patient. Transaminase peaks: 1, chronic hepatic GVHD; 2, HBV
hepatitis; 3, lamivudine effect. BCT, blood component transfusion; MP,
methylprednisolone; AZA, azathioprine; LAM, lamivudine.
the 2 preceding years; thus, the most likely explanation for
the acute hepatitis was viral reactivation. This means that
HBV may remain in the body as a latent infection even
when HBsAb and HBcAb are present, and that HBV infec-
tion may reactivate even after the disappearance of the anti-
bodies, as already suggested.9
Lamivudine as first line and single drug treatment proved
to be effective and well tolerated in our patient. It is still
uncertain how long the treatment should be maintained; a
reasonable option is to stop the treatment on serum HBeAg
disappearance, in order to avoid a possible rebound
effect.7,8 Finally, other studies are needed to explore the
efficacy of this drug as prophylaxis in BMT patients who
are HBsAg+ before transplant (analogous to liver transplant
patients),10 or who receive a bone marrow donation from
an HBsAg+ donor.
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